indirect comparison of elranatamab in magnetismm-3 versus real-world treatment regimens
Published 3 weeks ago • 48 plays • Length 1:35Download video MP4
Download video MP3
Similar videos
-
6:07
elranatamab for r/r myeloma: long-term updates from magnetismm-3 & real-world safety of this agent
-
3:27
patient-reported outcomes with the use of elranatamab in the magnetismm-3 trial
-
6:07
magnetismm-3: elranatamab in r/r multiple myeloma naive to bcma-directed therapy
-
5:49
magnetismm-3 extended follow up results: elranatamab monotherapy in r/r multiple myeloma
-
1:55
piccolo xpress with capillary tube
-
10:49
mayo clinic rochester
-
4:12
when should smoldering multiple myeloma patients start treatment?
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
2:12
magnetismm-1: investigating the efficacy of elranatamab in patients with r/r multiple myeloma
-
1:16
insights into the magnetismm-4 trial
-
3:16
magnetismm-3: elranatamab for myeloma
-
0:45
difference between quality of life & patient-reported outcomes
-
4:17
evaluating the safety and efficacy of elranatamab in multiple myeloma
-
10:39
magnetismm-3: elranatamab in relapsed/refractory multiple myeloma
-
4:01
matching-adjusted indirect comparison of elevate-tn versus sequoia
-
2:47
magnestismm-1: elranatamab alone or with immunomodulatory agents in r/r multiple myeloma
-
1:28
magnetismm-7: elranatamab vs lenalidomide following autohsct in mrd-positive newly diagnosed myeloma
-
1:37
the promise of elranatamab and other bispecifics in the treatment of myeloma
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:10
magnetismm-4: elranatamab in combination with other agents for patients with multiple myeloma